Cortico‐subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine

Fatigue in multiple sclerosis (MS) is common and disabling; medication efficacy is still not fully proven. The aim of this study was to investigate 4‐week modifications of fatigue severity in 45 relapsing‐remitting MS patients after different symptomatic treatments, and changes in concomitant resting state (RS) functional connectivity (FC).

[1]  F. Tecchio,et al.  Fatigue in multiple sclerosis: Does the functional or structural damage prevail? , 2020, Multiple sclerosis.

[2]  Scott Rooney,et al.  Minimally important difference of the fatigue severity scale and modified fatigue impact scale in people with multiple sclerosis. , 2019, Multiple sclerosis and related disorders.

[3]  S. T. Govindarajan,et al.  Resting-state functional connectivity networks associated with fatigue in multiple sclerosis with early age onset. , 2019, Multiple sclerosis and related disorders.

[4]  J. Lechner-Scott,et al.  Evaluation of MS related central fatigue using MR neuroimaging methods: Scoping review , 2019, Journal of the Neurological Sciences.

[5]  F. Paul,et al.  Multiple sclerosis–related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex , 2019, Multiple sclerosis.

[6]  M. Filippi,et al.  Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis , 2018, Multiple sclerosis.

[7]  P. Brugger,et al.  Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years , 2018, Journal of Neurology.

[8]  Li Wang,et al.  Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis , 2017, Journal of the Neurological Sciences.

[9]  M. Filippi,et al.  Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue , 2016, Multiple sclerosis.

[10]  F. Esposito,et al.  Fatigue in multiple sclerosis: The contribution of resting-state functional connectivity reorganization , 2018, Multiple sclerosis.

[11]  A. H. Ledinek,et al.  Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients , 2015, Clinical Neurology and Neurosurgery.

[12]  Patrizia Pantano,et al.  Resting-State fMRI in MS: General Concepts and Brief Overview of Its Application , 2015, BioMed research international.

[13]  F. Benedetti,et al.  Placebo‐induced decrease in fatigue: evidence for a central action on the preparatory phase of movement , 2015, The European journal of neuroscience.

[14]  F. Benedetti.  Placebo Effects: From the Neurobiological Paradigm to Translational Implications , 2014, Neuron.

[15]  J. Generali,et al.  Amantadine: Multiple Sclerosis–Related Fatigue , 2014, Hospital pharmacy.

[16]  U. Rot,et al.  Evaluating the effects of amantadin, modafinil and acetyl-l-carnitine on fatigue in multiple sclerosis – result of a pilot randomized, blind study , 2013, Clinical Neurology and Neurosurgery.

[17]  G. Wylie,et al.  Examination of Cognitive Fatigue in Multiple Sclerosis using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging , 2013, PloS one.

[18]  H. Hämäläinen,et al.  The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue , 2011, Multiple sclerosis.

[19]  G. Wylie,et al.  Functional neuroimaging of fatigue. , 2009, Physical medicine and rehabilitation clinics of North America.

[20]  S. Hayasaka,et al.  Power and sample size calculation for neuroimaging studies by non-central random field theory , 2007, NeuroImage.

[21]  G. Nagels,et al.  Multidisciplinary fatigue management programme in multiple sclerosis: a randomized clinical trial , 2007, Multiple sclerosis.

[22]  Massimo Filippi,et al.  fMRI changes in relapsing‐remitting multiple sclerosis patients complaining of fatigue after IFNβ‐1a injection , 2007, Human brain mapping.

[23]  A. Cross,et al.  Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study , 2007, Multiple sclerosis.

[24]  M. Filippi,et al.  Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes , 2005, The Lancet Neurology.

[25]  C. Pozzilli,et al.  Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine , 2004, Neurology.

[26]  A. Chaudhuri,et al.  Fatigue in neurological disorders , 2004, The Lancet.

[27]  C Trenkwalder,et al.  Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters , 2002, Multiple sclerosis.

[28]  J. Pekar,et al.  A method for making group inferences from functional MRI data using independent component analysis , 2001, Human brain mapping.

[29]  J. Rothwell,et al.  An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. , 1998, Brain : a journal of neurology.

[30]  Lauren B. Krupp,et al.  Fatigue in multiple sclerosis. , 1988, Archives of neurology.

[31]  B. Weinshenker,et al.  A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[32]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[33]  K. Rammohan,et al.  A variant in the HS1-BP3 gene is associated with familial essential tremor , 2005, Neurology.

[34]  K. Smith,et al.  Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. , 2000, Brain : a journal of neurology.

[35]  A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group. , 1987, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques.